Pure Biologics (STU:PQB) Notes Receivable: €0.00 Mil (As of Mar. 2026)


STU:PQB Pure Biologics SA STU:PQB
19 GF Score
Price €0.41
! 2 Warning Signs
View Full Analysis

What is Pure Biologics Notes Receivable?

Pure Biologics STU:PQB +0.73% 19 Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:PQB with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

Pure Biologics's Notes Receivable for the quarter that ended in Mar. 2026 was €0.00 Mil.

Pure Biologics Notes Receivable Historical Data

* Premium members only.

The historical data trend for Pure Biologics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pure Biologics Notes Receivable Chart

Pure Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Pure Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:PQB
19GF Score
Pure Biologics SA STU:PQB
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pure Biologics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
Pure Biologics (STU:PQB) has a Notes Receivable of €0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Pure Biologics and its competitors.
Is Pure Biologics' Notes Receivable too high?
Pure Biologics' current Notes Receivable is €0.00 Mil. Overall, Pure Biologics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Pure Biologics' Notes Receivable compare to VRTX and REGN?
Pure Biologics' Notes Receivable of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Pure Biologics and its competitors. Pure Biologics's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pure Biologics stock overvalued right now?
Pure Biologics (STU:PQB) has a current Notes Receivable of €0.00 Mil. The current Notes Receivable is €0.00 Mil. Pure Biologics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Pure Biologics (STU:PQB), the current Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pure Biologics Business Description

Other Exchanges PUR:Poland
Address ul. Dunska 11, Wroclaw, POL, 54-427
Pure Biologics SA is a Poland based biopharmaceutical company. It invests in the development of new, innovative (non-generic or biosimilar) biological drugs, medical and diagnostic products. It is mainly engaged in the research and development of the biologically active molecule in the drug development process. It specializes in the production and analysis of recombinant proteins and antibodies, contract studies of early product development phases, protein engineering, protein formulation, genomic sequencing, proteomics analysis and bioinformatics. Its projects include cancer immunotherapy, therapy of neurodegenerative diseases, diagnosis of tumors, and other partner projects.
19GF Score

Get the complete analysis for STU:PQB

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.41
Price